Coreg CR Gets Green Light for Generic Lifeline
Published Date: 5/30/2025
Notice
Summary
The FDA says COREG CR extended-release capsules (10, 20, 40, and 80 mg) weren’t pulled from shelves because of safety or effectiveness problems. This means generic versions can keep getting approved, so patients and pharmacies won’t face shortages or price spikes. If you use or make this medicine, things will keep running smoothly without any sudden changes.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Generics remain available; no shortages
The FDA determined that COREG CR (carvedilol phosphate) extended‑release capsules — 10 mg, 20 mg, 40 mg, and 80 mg — were not withdrawn from sale for reasons of safety or effectiveness. That means the FDA will continue to allow approval of generic versions, so patients and pharmacies won’t face sudden shortages or price spikes for these strengths.
ANDA approvals will continue for COREG CR
The FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to COREG CR extended‑release capsules (10 mg, 20 mg, 40 mg, 80 mg) and will allow continued approval of ANDAs that meet legal and regulatory requirements. This preserves the pathway for generic manufacturers and applicants to obtain approvals for these products.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20663, Agency Information Collection Activities; Proposed Collection; Comment Request; Channels of Trade Policy for Commodities With Residues of Pesticide Chemicals, for Which Tolerances Have Been Revoked, Suspended, or Modified by the Environmental Protection Agency Pursuant to Dietary Risk Considerations
The FDA wants your thoughts on how they collect info about food products that might have tiny amounts of banned or changed pesticides. This affects farmers, food sellers, and anyone handling these foods, making sure safety rules keep up with new pesticide limits. You’ve got until December 7, 2026, to share your views—no cost, just your voice!
Previous / Next Documents
Previous: 2025-09771, Report on the Performance of Drug and Biologics Firms in Conducting Postmarketing Requirements and Commitments; Availability
The FDA just released its yearly report on how drug and biologics companies are doing with their promised follow-up studies after approval. This report affects companies that make these products and helps everyone see if they’re keeping their promises to keep medicines safe. Check it out online anytime to see the latest updates—no extra cost or waiting needed!
Next: 2025-09773, Petition for Exemption; Summary of Petition Received; Pyka Inc.
Pyka Inc. asked the FAA to relax some rules so they can test and use their special delivery drones more easily. This change could speed up drone deliveries and help businesses save time and money. If approved, it affects drone operators and customers who want faster, smarter deliveries soon.